top of page
  • Active, not recruiting

NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in Hi R SMM

Updated: May 23, 2022

NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma


e-prism-elotuzumab

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma


Sponsor

Dana-Farber Cancer Institute


Collaborators

Bristol-Myers Squibb

Celgene

Blood Cancer Research Partnership

Multiple Myeloma Research Consortium

The Leukemia and Lymphoma Society


Multiple Locations


This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.